Damien Picard

Founder at Vaderis Therapeutics AG

Health Technology

Profile

Damien Picard is the founder of Vaderis Therapeutics AG.
He held the title of Senior Medical Director at the company, although he is no longer active in that role.

Damien Picard active positions

Companies	Position	Start
Vaderis Therapeutics AG Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd.	Founder	-

All active positions of Damien Picard

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Damien Picard's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Vaderis Therapeutics AG Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd.	Health Technology